<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35345699</PMID><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Neuropathic Pain in Neurologic Disorders: A Narrative Review.</ArticleTitle><Pagination><StartPage>e22419</StartPage><MedlinePgn>e22419</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e22419</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.22419</ELocationID><Abstract><AbstractText>Neuropathic pain is defined as a painful condition caused by neurological lesions or diseases. Sometimes, neurological disorders may also be associated with neuropathic pain, which can be challenging to manage. For example, multiple sclerosis (MS) may cause chronic centralized painful symptoms due to nerve damage. Other chronic neuropathic pain syndromes may occur in the form of post-stroke pain, spinal cord injury pain, and other central pain syndromes. Chronic neuropathic pain is associated with dysfunction, disability, depression, disturbed sleep, and reduced quality of life. Early diagnosis may help improve outcomes, and pain control can be an important factor in restoring function. There are more than 100 different types of peripheral neuropathy and those involving sensory neurons can provoke painful symptoms. Accurate diagnosis of peripheral neuropathy is essential for pain control. Further examples are represented by gluten neuropathy, which is an extraintestinal manifestation of gluten sensitivity and presents as a form of peripheral neuropathy; in these unusual cases, neuropathy may be managed with diet. Neuropathic pain has been linked to CoronaVirus Disease (COVID) infection both during acute infection and as a post-viral syndrome known as long COVID. In this last case, neuropathic pain relates to the host's response to the virus. However, neuropathic pain may occur after any critical illness and has been observed as part of a syndrome following intensive care unit hospitalization.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022, Mitsikostas et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mitsikostas</LastName><ForeName>Dimos-Dimitrios</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>First Department of Neurology, Eginition Hospital, National and Kapodistrian University of Athens, Athens, GRC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moka</LastName><ForeName>Eleni</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Creta Interclinic Hospital, Herakleion, GRC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orrillo</LastName><ForeName>Enrique</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pain Medicine, Asociacion Peruana para el Estudio del Dolor, Lima, PER.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aurilio</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, University of Napoli, Napoli, ITA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vadalouca</LastName><ForeName>Athina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pain and Palliative Care Center, Athens Medical Hospital, Athens, GRC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paladini</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Life, Health and Environmental Sciences (MESVA), University of L'Aquila, L'Aquila, ITA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varrassi</LastName><ForeName>Giustino</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Pain Management, Paolo Procacci Foundation, Rome, ITA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">long covid</Keyword><Keyword MajorTopicYN="N">multiple sclerosis</Keyword><Keyword MajorTopicYN="N">neurological disorders</Keyword><Keyword MajorTopicYN="N">neuropathic pain</Keyword><Keyword MajorTopicYN="N">pain</Keyword><Keyword MajorTopicYN="N">post-stroke pain</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>29</Day><Hour>5</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35345699</ArticleId><ArticleId IdType="pmc">PMC8942164</ArticleId><ArticleId IdType="doi">10.7759/cureus.22419</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>The neuropathic pain: an overview of the current treatment and future therapeutic approaches. Cavalli E, Mammana S, Nicoletti F, Bramanti P, Mazzon E. Int J Immunopathol Pharmacol. 2019;33:2058738419838383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6431761</ArticleId><ArticleId IdType="pubmed">30900486</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathic pain: definition, assessment and epidemiology. Bouhassira D. Rev Neurol (Paris) 2019;175:16&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">30385075</ArticleId></ArticleIdList></Reference><Reference><Citation>Classification, diagnosis, and differential diagnosis of multiple sclerosis. Katz Sand I. Curr Opin Neurol. 2015;28:193&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">25887774</ArticleId></ArticleIdList></Reference><Reference><Citation>The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. Karussis D. J Autoimmun. 2014;48-49:134&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">24524923</ArticleId></ArticleIdList></Reference><Reference><Citation>Idiopathic inflammatory-demyelinating diseases of the central nervous system. Ca&#xf1;ellas AR, Gols AR, Izquierdo JR, Subirana MT, Gairin XM. Neuroradiology. 2007;49:393&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">17333161</ArticleId></ArticleIdList></Reference><Reference><Citation>Altered human oligodendrocyte heterogeneity in multiple sclerosis. J&#xe4;kel S, Agirre E, Mendanha Falc&#xe3;o A, et al. Nature. 2019;566:543&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6544546</ArticleId><ArticleId IdType="pubmed">30747918</ArticleId></ArticleIdList></Reference><Reference><Citation>IFN-&#x3b2; and multiple sclerosis: cross-talking of immune cells and integration of immunoregulatory networks. Severa M, Rizzo F, Giacomini E, Salvetti M, Coccia EM. Cytokine Growth Factor Rev. 2015;26:229&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">25498525</ArticleId></ArticleIdList></Reference><Reference><Citation>Myelination of the nervous system: mechanisms and functions. Nave KA, Werner HB. Annu Rev Cell Dev Biol. 2014;30:503&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">25288117</ArticleId></ArticleIdList></Reference><Reference><Citation>Dynamics of oligodendrocyte generation in multiple sclerosis. Yeung MS, Djelloul M, Steiner E, et al. Nature. 2019;566:538&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6420067</ArticleId><ArticleId IdType="pubmed">30675058</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology of multiple sclerosis. Howard J, Trevick S, Younger DS. Neurol Clin. 2016;34:919&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">27720001</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology of multiple sclerosis. Leray E, Moreau T, Fromont A, Edan G. Rev Neurol (Paris) 2016;172:3&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">26718593</ArticleId></ArticleIdList></Reference><Reference><Citation>Multiple sclerosis prevalence in the United States commercially insured population. Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Neurology. 2016;86:1014&#x2013;1021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4799713</ArticleId><ArticleId IdType="pubmed">26888980</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology of multiple sclerosis in Santiago de Compostela (Spain) Costa Arp&#xed;n E, Naveiro Soneira J, Lema Bouzas M, Gonz&#xe1;lez Quintela A, Prieto Gonz&#xe1;lez JM. Acta Neurol Scand. 2020;142:267&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">32392359</ArticleId></ArticleIdList></Reference><Reference><Citation>Changes in multiple sclerosis epidemiology in Finland over five decades. Pirttisalo AL, Soilu-H&#xe4;nninen M, Sumelahti ML, et al. Acta Neurol Scand. 2020;142:200&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">32500607</ArticleId></ArticleIdList></Reference><Reference><Citation>Why does the North-South gradient of incidence of multiple sclerosis seem to have disappeared on the northern hemisphere? Koch-Henriksen N, Sorensen PS. J Neurol Sci. 2011;311:58&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">21982346</ArticleId></ArticleIdList></Reference><Reference><Citation>Multiple Sclerosis News Today. MS statistics: multiple sclerosis news today; 2020 [updated March 5, 2020; cited 2021 December 1] https://multiplesclerosisnewstoday.com/multiple-sclerosis-overview/statistics/ 2020;5:2020&#x2013;2021.</Citation></Reference><Reference><Citation>Multiple sclerosis. Compston A, Coles A. Lancet. 2008;372:0&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">18970977</ArticleId></ArticleIdList></Reference><Reference><Citation>Defining the clinical course of multiple sclerosis: the 2013 revisions. Lublin FD, Reingold SC, Cohen JA, et al. Neurology. 2014;83:278&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117366</ArticleId><ArticleId IdType="pubmed">24871874</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical course of multiple sclerosis. Klineova S, Lublin FD. Cold Spring Harb Perspect Med. 2018;8:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6120692</ArticleId><ArticleId IdType="pubmed">29358317</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinically isolated syndromes. Miller DH, Chard DT, Ciccarelli O. Lancet Neurol. 2012;11:157&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">22265211</ArticleId></ArticleIdList></Reference><Reference><Citation>Advances in the understanding and management of chronic pain in multiple sclerosis: a comprehensive review. Urits I, Adamian L, Fiocchi J, et al. Curr Pain Headache Rep. 2019;23:59.</Citation><ArticleIdList><ArticleId IdType="pubmed">31342191</ArticleId></ArticleIdList></Reference><Reference><Citation>An update on the pharmacological management of pain in patients with multiple sclerosis. Chisari CG, Sgarlata E, Arena S, D'Amico E, Toscano S, Patti F. Expert Opin Pharmacother. 2020;21:2249&#x2013;2263.</Citation><ArticleIdList><ArticleId IdType="pubmed">32343626</ArticleId></ArticleIdList></Reference><Reference><Citation>Pain and multiple sclerosis: pathophysiology and treatment. Solaro C, Trabucco E, Messmer Uccelli M. Curr Neurol Neurosci Rep. 2013;13:320.</Citation><ArticleIdList><ArticleId IdType="pubmed">23250765</ArticleId></ArticleIdList></Reference><Reference><Citation>Pain and MS. Solaro C, Lunardi GL, Mancardi GL. https://pubmed.ncbi.nlm.nih.gov/12906765/ Int MS J. 2003;10:14&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">12906765</ArticleId></ArticleIdList></Reference><Reference><Citation>Headache in systemic lupus erythematosus vs multiple sclerosis: a prospective comparative study. Katsiari CG, Vikelis M, Paraskevopoulou ES, Sfikakis PP, Mitsikostas DD. Headache. 2011;51:1398&#x2013;1407.</Citation><ArticleIdList><ArticleId IdType="pubmed">21797859</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevalence of primary headaches in people with multiple sclerosis. D'Amico D, La Mantia L, Rigamonti A, et al. Cephalalgia. 2004;24:980&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pubmed">15482362</ArticleId></ArticleIdList></Reference><Reference><Citation>Headache in multiple sclerosis: features and implications for disease management. Tabby D, Majeed MH, Youngman B, Wilcox J. Int J MS Care. 2013;15:73&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3883008</ArticleId><ArticleId IdType="pubmed">24453766</ArticleId></ArticleIdList></Reference><Reference><Citation>Migraine is comorbid with multiple sclerosis and associated with a more symptomatic MS course. Kister I, Caminero AB, Monteith TS, et al. J Headache Pain. 2010;11:417&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3452278</ArticleId><ArticleId IdType="pubmed">20625916</ArticleId></ArticleIdList></Reference><Reference><Citation>Migraine headache associated with multiple sclerosis: results from the nationwide inpatient sample. Koffman B. Translation: The University of Toledo Journal of Medical Sciences. 2021;4:1&#x2013;5.</Citation></Reference><Reference><Citation>Why do multiple sclerosis and migraine coexist? Hamamc&#x131; M, G&#xf6;cmen AY, Say B, et al. Mult Scler Relat Disord. 2020;40:101946.</Citation><ArticleIdList><ArticleId IdType="pubmed">31982663</ArticleId></ArticleIdList></Reference><Reference><Citation>The prevalence of migraine in multiple sclerosis (MS): a systematic review and meta-analysis. Mirmosayyeb O, Barzegar M, Nehzat N, Shaygannejad V, Sahraian MA, Ghajarzadeh M. J Clin Neurosci. 2020;79:33&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">33070914</ArticleId></ArticleIdList></Reference><Reference><Citation>Migraine and multiple sclerosis: epidemiology and approach to treatment. Gelfand AA, Gelfand JM, Goadsby PJ. Mult Scler Relat Disord. 2013;2:73&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">25877626</ArticleId></ArticleIdList></Reference><Reference><Citation>21st century headache: mapping new territory. Goadsby PJ, Lant&#xe9;ri-Minet M, Michel MC, et al. J Headache Pain. 2021;22:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8015309</ArticleId><ArticleId IdType="pubmed">33794761</ArticleId></ArticleIdList></Reference><Reference><Citation>Non-pharmacological interventions for chronic pain in multiple sclerosis. Amatya B, Young J, Khan F. Cochrane Database Syst Rev. 2018;12:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6516893</ArticleId><ArticleId IdType="pubmed">30567012</ArticleId></ArticleIdList></Reference><Reference><Citation>Influence of yoga and aerobics exercise on fatigue, pain and psychosocial status in patients with multiple sclerosis: a randomized trial. Hasanpour Dehkordi A. https://pubmed.ncbi.nlm.nih.gov/26223004/ J Sports Med Phys Fitness. 2016;56:1417&#x2013;1422.</Citation><ArticleIdList><ArticleId IdType="pubmed">26223004</ArticleId></ArticleIdList></Reference><Reference><Citation>Exercise prescription for patients with multiple sclerosis: potential benefits and practical recommendations. Halabchi F, Alizadeh Z, Sahraian MA, Abolhasani M. BMC Neurol. 2017;17:185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5602953</ArticleId><ArticleId IdType="pubmed">28915856</ArticleId></ArticleIdList></Reference><Reference><Citation>Assessment and measurement of spasticity in MS: state of the evidence. Hugos CL, Cameron MH. Curr Neurol Neurosci Rep. 2019;19:79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6948104</ArticleId><ArticleId IdType="pubmed">31471769</ArticleId></ArticleIdList></Reference><Reference><Citation>Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition. Walton C, King R, Rechtman L, et al. Mult Scler. 2020;26:1816&#x2013;1821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7720355</ArticleId><ArticleId IdType="pubmed">33174475</ArticleId></ArticleIdList></Reference><Reference><Citation>Diagnosis and treatment of pain in small-fiber neuropathy. Hovaguimian A, Gibbons CH. Curr Pain Headache Rep. 2011;15:193&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086960</ArticleId><ArticleId IdType="pubmed">21286866</ArticleId></ArticleIdList></Reference><Reference><Citation>Distal symmetric polyneuropathy: a review. Callaghan BC, Price RS, Feldman EL. JAMA. 2015;314:2172&#x2013;2181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5125083</ArticleId><ArticleId IdType="pubmed">26599185</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacological management of painful peripheral neuropathies: a systematic review. Liampas A, Rekatsina M, Vadalouca A, Paladini A, Varrassi G, Zis P. Pain Ther. 2021;10:55&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8119529</ArticleId><ArticleId IdType="pubmed">33145709</ArticleId></ArticleIdList></Reference><Reference><Citation>Peripheral neuropathy.  [
Nov;
2022 
];Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/peripheral-neuropathy/symptoms-causes/syc-20352061 Mayo Clinic, Rochester, Minnesota. 2019 </Citation></Reference><Reference><Citation>Peripheral neuropathy. Barrell K, Smith AG. Med Clin North Am. 2019;103:383&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">30704689</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology of peripheral neuropathy. Martyn CN, Hughes RA. J Neurol Neurosurg Psychiatry. 1997;62:310&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1074084</ArticleId><ArticleId IdType="pubmed">9120441</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation in two Italian regions. I. Prevalence and general characteristics of the sample. Italian General Practitioner Study Group (IGPSG) https://moh-it.pure.elsevier.com/en/publications/chronic-symmetric-symptomatic-polyneuropathy-in-the-elderly-a-fie-2. Neurology. 1995;45:1832&#x2013;1836.</Citation><ArticleIdList><ArticleId IdType="pubmed">7477977</ArticleId></ArticleIdList></Reference><Reference><Citation>Central obesity is associated with neuropathy in the severely obese. Callaghan BC, Reynolds E, Banerjee M, Chant E, Villegas-Umana E, Feldman EL. Mayo Clin Proc. 2020;95:1342&#x2013;1353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7340115</ArticleId><ArticleId IdType="pubmed">32622444</ArticleId></ArticleIdList></Reference><Reference><Citation>Peripheral neuropathy: a practical approach to diagnosis and symptom management. Watson JC, Dyck PJ. Mayo Clin Proc. 2015;90:940&#x2013;951.</Citation><ArticleIdList><ArticleId IdType="pubmed">26141332</ArticleId></ArticleIdList></Reference><Reference><Citation>Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. England JD, Gronseth GS, Franklin G, et al. Neurology. 2009;72:185&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">19056666</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug-induced peripheral neuropathy: a narrative review. Jones MR, Urits I, Wolf J, et al. Curr Clin Pharmacol. 2020;15:38&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7365998</ArticleId><ArticleId IdType="pubmed">30666914</ArticleId></ArticleIdList></Reference><Reference><Citation>Quality of life in painful peripheral neuropathies: a systematic review. Girach A, Julian TH, Varrassi G, Paladini A, Vadalouka A, Zis P. Pain Res Manag. 2019;2019:2091960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6556282</ArticleId><ArticleId IdType="pubmed">31249636</ArticleId></ArticleIdList></Reference><Reference><Citation>Quality of life in patients with gluten neuropathy: a case-controlled study. Zis P, Sarrigiannis PG, Rao DG, Hadjivassiliou M. Nutrients. 2018;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6024358</ArticleId><ArticleId IdType="pubmed">29882897</ArticleId></ArticleIdList></Reference><Reference><Citation>Gluten sensitivity: from gut to brain. Hadjivassiliou M, Sanders DS, Gr&#xfc;newald RA, et al. Lancet Neurol. 2010;9:318&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">20170845</ArticleId></ArticleIdList></Reference><Reference><Citation>Gluten neuropathy: prevalence of neuropathic pain and the role of gluten-free diet. Zis P, Sarrigiannis PG, Rao DG, Hadjivassiliou M. J Neurol. 2018;265:2231&#x2013;2236.</Citation><ArticleIdList><ArticleId IdType="pubmed">30032386</ArticleId></ArticleIdList></Reference><Reference><Citation>The multiple challenges of neuropathic pain. Bouhassira D, Attal N. Neurosci Lett. 2019;702:6&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">30503925</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathic pain: redefinition and a grading system for clinical and research purposes. Treede RD, Jensen TS, Campbell JN, et al. Neurology. 2008;70:1630&#x2013;1635.</Citation><ArticleIdList><ArticleId IdType="pubmed">18003941</ArticleId></ArticleIdList></Reference><Reference><Citation>IASP terminology.  [
Sep;
2022 
];International Association for the Study of Pain. https://www.iasp-pain.org/Education/Content.aspx International Association for the Study of Pain. 2020 </Citation></Reference><Reference><Citation>The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Scholz J, Finnerup NB, Attal N, et al. Pain. 2019;160:53&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6310153</ArticleId><ArticleId IdType="pubmed">30586071</ArticleId></ArticleIdList></Reference><Reference><Citation>Herpes zoster oticus, ophthalmicus, and cutaneous disseminated: case report and literature review. Pitton Rissardo J, Fornari Caprara AL. Neuroophthalmology. 2019;43:407&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7053943</ArticleId><ArticleId IdType="pubmed">32165902</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathic pain. Colloca L, Ludman T, Bouhassira D, et al. Nat Rev Dis Primers. 2017;3:17002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5371025</ArticleId><ArticleId IdType="pubmed">28205574</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathic pain: from mechanisms to treatment. Finnerup NB, Kuner R, Jensen TS. Physiol Rev. 2021;101:259&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">32584191</ArticleId></ArticleIdList></Reference><Reference><Citation>The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. Torrance N, Smith BH, Bennett MI, Lee AJ. J Pain. 2006;7:281&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">16618472</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevalence of chronic pain with neuropathic characteristics in the general population. Bouhassira D, Lant&#xe9;ri-Minet M, Attal N, Laurent B, Touboul C. Pain. 2008;136:380&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">17888574</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathic pain in the general population: a systematic review of epidemiological studies. van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Pain. 2014;155:654&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">24291734</ArticleId></ArticleIdList></Reference><Reference><Citation>A burden of illness study for neuropathic pain in Europe. Liedgens H, Obradovic M, De Courcy J, Holbrook T, Jakubanis R. Clinicoecon Outcomes Res. 2016;8:113&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4853004</ArticleId><ArticleId IdType="pubmed">27217785</ArticleId></ArticleIdList></Reference><Reference><Citation>A review of neuropathic pain: from guidelines to clinical practice. Cruccu G, Truini A. Pain Ther. 2017;6:35&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5701894</ArticleId><ArticleId IdType="pubmed">29178033</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Finnerup NB, Attal N, Haroutounian S, et al. Lancet Neurol. 2015;14:162&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4493167</ArticleId><ArticleId IdType="pubmed">25575710</ArticleId></ArticleIdList></Reference><Reference><Citation>Interventional management of neuropathic pain: NeuPSIG recommendations. Dworkin RH, O'Connor AB, Kent J, et al. Pain. 2013;154:2249&#x2013;2261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4484720</ArticleId><ArticleId IdType="pubmed">23748119</ArticleId></ArticleIdList></Reference><Reference><Citation>NeuPSIG guidelines on neuropathic pain assessment. Haanp&#xe4;&#xe4; M, Attal N, Backonja M, et al. Pain. 2011;152:14&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">20851519</ArticleId></ArticleIdList></Reference><Reference><Citation>EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Attal N, Cruccu G, Baron R, et al. Eur J Neurol. 2010;17:1113&#x2013;1110.</Citation><ArticleIdList><ArticleId IdType="pubmed">20402746</ArticleId></ArticleIdList></Reference><Reference><Citation>EFNS guidelines on neuropathic pain assessment: revised 2009. Cruccu G, Sommer C, Anand P, et al. Eur J Neurol. 2010;17:1010&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pubmed">20298428</ArticleId></ArticleIdList></Reference><Reference><Citation>EFNS guidelines on neurostimulation therapy for neuropathic pain. Cruccu G, Aziz TZ, Garcia-Larrea L, et al. Eur J Neurol. 2007;14:952&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pubmed">17718686</ArticleId></ArticleIdList></Reference><Reference><Citation>Evidence-based guideline for neuropathic pain interventional treatments: spinal cord stimulation, intravenous infusions, epidural injections and nerve blocks. Mailis A, Taenzer P. Pain Res Manag. 2012;17:150&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3401085</ArticleId><ArticleId IdType="pubmed">22606679</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Moulin D, Boulanger A, Clark AJ, et al. Pain Res Manag. 2014;19:328&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4273712</ArticleId><ArticleId IdType="pubmed">25479151</ArticleId></ArticleIdList></Reference><Reference><Citation>Comorbidities in chronic neuropathic pain. Nicholson B, Verma S. Pain Med. 2004;5(Suppl 1):0.</Citation><ArticleIdList><ArticleId IdType="pubmed">14996227</ArticleId></ArticleIdList></Reference><Reference><Citation>The impact of neuropathic pain on health-related quality of life: review and implications. Jensen MP, Chodroff MJ, Dworkin RH. Neurology. 2007;68:1178&#x2013;1182.</Citation><ArticleIdList><ArticleId IdType="pubmed">17420400</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology of neuropathic pain and its impact on quality of life. Smith BH, Torrance N. Curr Pain Headache Rep. 2012;16:191&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">22395856</ArticleId></ArticleIdList></Reference><Reference><Citation>Unmet needs in the management of functional impairment in patients with chronic pain: a multinational survey. Karra R, Holten-Rossing S, Mohammed D, Parmeggiani L, Heine M, Namn&#xfa;n OC. Pain Manag. 2021;11:303&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">33353407</ArticleId></ArticleIdList></Reference><Reference><Citation>Assessment of neuropathic pain in primary care. Haanp&#xe4;&#xe4; ML, Backonja MM, Bennett MI, et al. Am J Med. 2009;122:0.</Citation><ArticleIdList><ArticleId IdType="pubmed">19801048</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical practice guidelines for the management of neuropathic pain: a systematic review. Deng Y, Luo L, Hu Y, Fang K, Liu J. BMC Anesthesiol. 2016;16:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4759966</ArticleId><ArticleId IdType="pubmed">26892406</ArticleId></ArticleIdList></Reference><Reference><Citation>A comprehensive algorithm for management of neuropathic pain. Bates D, Schultheis BC, Hanes MC, et al. Pain Med. 2019;20:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6544553</ArticleId><ArticleId IdType="pubmed">31152178</ArticleId></ArticleIdList></Reference><Reference><Citation>Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment. Vadalouca A, Siafaka I, Argyra E, Vrachnou E, Moka E. Ann N Y Acad Sci. 2006;1088:164&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192564</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature. Vadalouca A, Raptis E, Moka E, Zis P, Sykioti P, Siafaka I. Pain Pract. 2012;12:219&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">21797961</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathic pain: models and mechanisms. Jarvis MF, Boyce-Rustay JM. Curr Pharm Des. 2009;15:1711&#x2013;1716.</Citation><ArticleIdList><ArticleId IdType="pubmed">19442185</ArticleId></ArticleIdList></Reference><Reference><Citation>The relevance of neuropathic components in chronic back pain. Morlion B. Curr Med Res Opin. 2011;27:2067&#x2013;2068.</Citation><ArticleIdList><ArticleId IdType="pubmed">21929439</ArticleId></ArticleIdList></Reference><Reference><Citation>Botulinum toxin for the treatment of neuropathic pain. Park J, Park HJ. Toxins (Basel) 2017;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5618193</ArticleId><ArticleId IdType="pubmed">28837075</ArticleId></ArticleIdList></Reference><Reference><Citation>Botulinum toxin treatment of pain syndromes: an evidence based review. Safarpour Y, Jabbari B. Toxicon. 2018;147:120&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">29409817</ArticleId></ArticleIdList></Reference><Reference><Citation>Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Kajdasz DK, Iyengar S, Desaiah D, et al. Clin Ther. 2007;29(Suppl):2536&#x2013;2546.</Citation><ArticleIdList><ArticleId IdType="pubmed">18164920</ArticleId></ArticleIdList></Reference><Reference><Citation>Summary measures of number needed to treat: how much clinical guidance do they provide in neuropathic pain? Edelsberg J, Oster G. Eur J Pain. 2009;13:11&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">18456524</ArticleId></ArticleIdList></Reference><Reference><Citation>Multimodal analgesia in moderate-to-severe pain: a role for a new fixed combination of dexketoprofen and tramadol. Varrassi G, Hanna M, Macheras G, et al. Curr Med Res Opin. 2017;33:1165&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pubmed">28326850</ArticleId></ArticleIdList></Reference><Reference><Citation>Rationale for the use of adjuvants in acute pain. Varrassi G, De Nicola A. https://pubmed.ncbi.nlm.nih.gov/1784389/ Minerva Anestesiol. 1991;57:1271&#x2013;1274.</Citation><ArticleIdList><ArticleId IdType="pubmed">1784389</ArticleId></ArticleIdList></Reference><Reference><Citation>Combination therapy for neuropathic pain: a review of recent evidence. Serrano Afonso A, Carnaval T, Videla C&#xe9;s S. J Clin Med. 2021;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8396869</ArticleId><ArticleId IdType="pubmed">34441829</ArticleId></ArticleIdList></Reference><Reference><Citation>Combination pharmacotherapy for the treatment of neuropathic pain in adults. Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Cochrane Database Syst Rev. 2012;2012:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6481651</ArticleId><ArticleId IdType="pubmed">22786518</ArticleId></ArticleIdList></Reference><Reference><Citation>Combination of morphine with nortriptyline for neuropathic pain. Gilron I, Tu D, Holden RR, Jackson AC, DuMerton-Shore D. Pain. 2015;156:1440&#x2013;1448.</Citation><ArticleIdList><ArticleId IdType="pubmed">25749306</ArticleId></ArticleIdList></Reference><Reference><Citation>Combination treatment of neuropathic pain: Danish expert recommendations based on a Delphi process. Holbech JV, Jung A, Jonsson T, Wanning M, Bredahl C, Bach FW. J Pain Res. 2017;10:1467&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5499948</ArticleId><ArticleId IdType="pubmed">28721089</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxycodone for neuropathic pain in adults. Gaskell H, Derry S, Stannard C, Moore RA. Cochrane Database Syst Rev. 2016;7:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6457997</ArticleId><ArticleId IdType="pubmed">27465317</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapentadol extended release in the treatment of severe chronic low back pain and osteoarthritis pain. Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, Raffa RB, Bisney J. Pain Ther. 2018;7:37&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5993688</ArticleId><ArticleId IdType="pubmed">29623654</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxcarbazepine for neuropathic pain. Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Cochrane Database Syst Rev. 2017;12:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6486101</ArticleId><ArticleId IdType="pubmed">29199767</ArticleId></ArticleIdList></Reference><Reference><Citation>Medical cannabis for neuropathic pain. Lee G, Grovey B, Furnish T, Wallace M. Curr Pain Headache Rep. 2018;22:8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29388063</ArticleId></ArticleIdList></Reference><Reference><Citation>Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Argoff CE, Backonja MM, Belgrade MJ, et al. Mayo Clin Proc. 2006;81:12&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">16608049</ArticleId></ArticleIdList></Reference><Reference><Citation>Potential for increased prevalence of neuropathic pain after the COVID-19 pandemic. Attal N, Martinez V, Bouhassira D. Pain Rep. 2021;6:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7850724</ArticleId><ArticleId IdType="pubmed">33537521</ArticleId></ArticleIdList></Reference><Reference><Citation>It's not over till it's over: a narrative review of Long COVID. Pergolizzi J, LeQuang J, Magnusson P, et al. Signa Vitae. 2021;17:21&#x2013;30.</Citation></Reference><Reference><Citation>Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Cantuti-Castelvetri L, Ojha R, Pedro LD, et al. Science. 2020;370:856&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857391</ArticleId><ArticleId IdType="pubmed">33082293</ArticleId></ArticleIdList></Reference><Reference><Citation>Potential neurological manifestations of COVID-19: a narrative review. Pergolizzi JV Jr, Raffa RB, Varrassi G, et al. Postgrad Med. 2021;[Epub ahead of print]:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799377</ArticleId><ArticleId IdType="pubmed">33089707</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Baron R, Binder A, Wasner G. Lancet Neurol. 2010;9:807&#x2013;819.</Citation><ArticleIdList><ArticleId IdType="pubmed">20650402</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathic pain: a practical guide for the clinician. Gilron I, Watson CP, Cahill CM, Moulin DE. CMAJ. 2006;175:265&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1513412</ArticleId><ArticleId IdType="pubmed">16880448</ArticleId></ArticleIdList></Reference><Reference><Citation>Nociceptors are interleukin-1beta sensors. Binshtok AM, Wang H, Zimmermann K, et al. J Neurosci. 2008;28:14062&#x2013;14073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690713</ArticleId><ArticleId IdType="pubmed">19109489</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropilin-1 is a host factor for SARS-CoV-2 infection. Daly JL, Simonetti B, Klein K, et al. Science. 2020;370:861&#x2013;865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7612957</ArticleId><ArticleId IdType="pubmed">33082294</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropilin&#x2011;1 as a new potential SARS&#x2011;CoV&#x2011;2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID&#x2011;19. Davies J, Randeva HS, Chatha K, et al. Mol Med Rep. 2020;22:4221&#x2013;4226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7533503</ArticleId><ArticleId IdType="pubmed">33000221</ArticleId></ArticleIdList></Reference><Reference><Citation>Endothelial cell control of thrombosis. Yau JW, Teoh H, Verma S. BMC Cardiovasc Disord. 2015;15:130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4617895</ArticleId><ArticleId IdType="pubmed">26481314</ArticleId></ArticleIdList></Reference><Reference><Citation>Endothelium infection and dysregulation by SARS-CoV-2: evidence and caveats in COVID-19. Bernard I, Limonta D, Mahal LK, Hobman TC. Viruses. 2020;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7823949</ArticleId><ArticleId IdType="pubmed">33375371</ArticleId></ArticleIdList></Reference><Reference><Citation>Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. J Clin Med. 2020;9:1417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7290769</ArticleId><ArticleId IdType="pubmed">32403217</ArticleId></ArticleIdList></Reference><Reference><Citation>Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Sardu C, D'Onofrio N, Balestrieri ML, et al. Diabetes Care. 2020;43:1408&#x2013;1415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7305003</ArticleId><ArticleId IdType="pubmed">32430456</ArticleId></ArticleIdList></Reference><Reference><Citation>Post-COVID 19 neurological syndrome (PCNS): a novel syndrome with challenges for the global neurology community. Wijeratne T, Crewther S. J Neurol Sci. 2020;419:117179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7550857</ArticleId><ArticleId IdType="pubmed">33070003</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurological associations of COVID-19. Ellul MA, Benjamin L, Singh B, et al. Lancet Neurol. 2020;19:767&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332267</ArticleId><ArticleId IdType="pubmed">32622375</ArticleId></ArticleIdList></Reference><Reference><Citation>Post-ICU syndrome: rescuing the undiagnosed. Myers EA, Smith DA, Allen SR, Kaplan LJ. JAAPA. 2016;29:34&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">27023654</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. Rodr&#xed;guez Y, Vatti N, Ram&#xed;rez-Santana C, et al. J Autoimmun. 2019;102:8&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">31072742</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronic pain after COVID-19: implications for rehabilitation. Kemp HI, Corner E, Colvin LA. Br J Anaesth. 2020;125:436&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7261464</ArticleId><ArticleId IdType="pubmed">32560913</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronic pain in critical care survivors: a narrative review. Kemp HI, Laycock H, Costello A, Brett SJ. Br J Anaesth. 2019;123:0&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6676238</ArticleId><ArticleId IdType="pubmed">31126622</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>